Black Diamond Therapeutics Reports Q3 GAAP EPS of -$0.17 and Strong Cash Position
Black Diamond Therapeutics (NASDAQ: BDTX) has reported its third-quarter financial results, posting a GAAP earnings per share (EPS) loss of $0.17. Despite the quarterly loss, the biotechnology company maintains a robust liquidity position with cash, cash equivalents, and investments totaling $102.0 million as of September 30, 2026. The company's current capital reserves are projected to provide sufficient funding for its operational requirements through the second half of 2028. While recent market sentiment has been affected by delays in clinical trial results leading to analyst downgrades, the firm's long-term cash runway remains a key factor for investors monitoring its development pipeline.
Tickers: $BDTX
Topics: cash runway earnings report GAAP EPS